Lv1
72 积分 2026-03-12 加入
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
1个月前
已完结
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
1个月前
已完结
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype
1个月前
已完结
Clinical effectiveness and safety of dupilumab in patients with chronic obstructive pulmonary disease: A 7-year population-based cohort study
1个月前
已完结
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
1个月前
已完结
FC 036IPTACOPAN (LNP023): A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY AND EFFECTIVELY STABILISES EGFR IN C3 GLOMERULOPATHY
1个月前
已关闭
The complement system: Biology, pathology, and therapeutic interventions
1个月前
已完结
IgA Nephropathy in Adults
1个月前
已完结
The complement system: Biology, pathology, and therapeutic interventions
1个月前
已完结
Analysis of the prevalence of systemic de novo thrombotic microangiopathy after ABO‐incompatible kidney transplantation and the associated risk factors
1个月前
已完结
皖公网安备34019202002308
